Pfizer announced that it has completed the acquisition of Baxter International´s portfolio of marketed vaccines, which consists of Neis Vac-C and FSME-Immun/Tico Vac. As previously reported, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
Pfizer aquired not only the portfolio of marketed vaccines of Baxter International, also a facility of the company in Orth, Austria, is now part of Pfizer.
(Picture: Pfizer)
New York/USA – “Neis Vac-C and FSME-Immun/Tico Vac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases.”
Neis Vac-C is a vaccine that helps protect against meningitis caused by group C meningococci (Men C). This serious infection of the membrane covering the brain may be fatal in roughly 10 to 15 percent of patients and 30 percent to more than 50 percent of survivors may suffer from severe physical, social and mental damage. Men C is one of the most prevalent meningococcal serogroups in many parts of the world and vaccination with Neis Vac-C has been shown to be highly effective.
FSME-Immun/Tico Vac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus. Every year, the TBE virus causes thousands of cases of neuroinvasive illness in humans across Europe and Asia and is a growing public health concern in Europe and other parts of the world. FSME-Immun/Tico Vac is approved in 30 countries and has been marketed for over 30 years with approximately 120 million doses produced since 1976.
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.